Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BG Medicine and ACS Biomarker have entered into an agreement pursuant to which BG Medicine has obtained rights to develop and commercialize a novel clinical diagnostic test for acute atherothrombosis.
Subscribe to our email newsletter
Under the terms of the agreement, ACS Biomarker has granted BG Medicine exclusive, worldwide commercial rights to pursue the development, validation, regulatory approval and commercialization of diagnostic tests based on the biomarker discovered by Cardiovascular Research Institute Maastricht (CARIM), in exchange for milestone payments, royalties based on net sales and sublicensing income of any products commercialized under the license.
The novel test that BG Medicine expects to develop aims to use the biomarker discovered by CARIM to identify plaque rupture in patients early, for instance, when the blockage is temporary or not complete and has not yet caused the common signs and symptoms of heart attack or stroke.
Specifically, the test aims to aid in the diagnosis of less severe or transient conditions such as transient ischemic attacks, cerebrovascular disorders that are often considered ‘warning-strokes’ which produce stroke-like symptoms, and unstable angina.